-- 据彭博社周一援引知情人士报道，汇丰控股(HKG:0005)一位负责部分债券业务的高级官员即将离职，加盟竞争对手美国银行。这是近期汇丰高管离职的第二起。 知情人士告诉彭博社，汇丰中东欧、中东及非洲地区债务资本市场主管哈立德·达尔维什(Khaled Darwish)将离开该职位，前往迪拜担任美国银行中东及北非企业银行业务主管。 达尔维什的离职紧随努尔·萨法(Nour Safa)之后。萨法此前负责汇丰中东及北非地区的债务资本市场业务。据报道，萨法将加入高盛集团。 （市场动态新闻来源于与全球市场专业人士的对话。我们认为这些信息来自可靠来源，但可能包含传闻和猜测。我们不保证其准确性。）
Related Articles
Research
Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315
Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$ADBE
US Markets
Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal
Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.
$OGN
Research
Morgan Stanley Initiates StubHub Holdings at Equalweight With $8.25 Price Target
StubHub Holdings (STUB) has an average rating of overweight and mean price target of $12.95, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$STUB